Project/Area Number |
08671824
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Saga Medical school |
Principal Investigator |
ICHIGI Yasuhisa Saga Medical school, Medical department, Assistant Professor, 医学部, 講師 (00193441)
|
Co-Investigator(Kenkyū-buntansha) |
SATO Shinji Saga Medical school, Medical department, Instructor, 医学部, 助手 (10244013)
|
Project Period (FY) |
1996 – 1998
|
Project Status |
Completed (Fiscal Year 1998)
|
Budget Amount *help |
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 1998: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1997: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1996: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
Keywords | prostate cancer / molecular staging / PCR |
Research Abstract |
Background. It was reported that about 50% of patients undergoing radical prostatectomy for presumed organ-confined prostate adenocarcinoma demonstrate rising serum PSA levels by 4 years postoperatively. This investigation was designed to confirm whether micrometastasis undetectable by conventional pathology could have explained these biochemical relapses. Methods. Pelvic lymph node which was dissected at the time of retropubic radical prostatectomy for adenocarcinoma was undertaken using a reverse transcription-polymerase chain reaction (RT-PCR) assay designed to amplify mRNA from PSA.The assay was compared with pathological staging, and patients were monitored postoperatively by serum PSA level. Results. Samples were obtained from 16 patients. Postoperative pathology revealed that one patients had pelvic lymph node metastasis at the time of surgery and the other 15 patients were free from pelvic lymph node metastasis. The RT-PCR assay was negative for 12 patients and positive for 3 patients without pelvic lymph node metastasis. Serum PSA level slightly elevated in only 3 patients who were RT-PCR-positive. Conclusion. These results suggest that micrometastasis may be detected by RT-PCR assay and molecular staging will differentiate more curable patients from those who are pathologically organ-confined disease.
|